Gunagratinib (Synonyms: ICP-192) |
Catalog No.GC64875 |
Le gunagratinib (ICP-192) est un inhibiteur pan-FGFR (récepteurs du facteur de croissance des fibroblastes) À faible toxicité et actif par voie orale qui inhibe puissamment et sélectivement les activités du FGFR de manière irréversible par liaison covalente. Le gunagratinib peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2211082-53-8
Sample solution is provided at 25 µL, 10mM.
Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1].
Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding[1].
[1]. Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *